Waki Hosoda
Waki Hosoda publishes mostly in Oncology, Surgery and Pulmonary and Respiratory Medicine, on topics such as Pancreatic and Hepatic Oncology Research, Neuroendocrine Tumor Research Advances and Lung Cancer Research Studies.
- World rank
- #679,315 of 7,710,434 ranked researchers
- Rank in Japan
- #7,809 of 383,136
- Works
- 168
- Citations
- 3.7k
- Citations per work
- 21.8
What does Waki Hosoda research?
Waki Hosoda's work is mostly in Medicine (70%), Biochemistry, Genetics and Molecular Biology (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences11769.6%
- Medicine11769.6%
- Everything else4124.3%
- Life Sciences106.1%
- 1Oncology27% of their works
- 2Surgery16% of their works
- 3Pulmonary and Respiratory Medicine11% of their works
- 4Epidemiology10% of their works
- 5Pathology and Forensic Medicine7% of their works
- 6Cancer Research6% of their works
Research topics
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Pancreatitis Pathology and Treatment
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Genetic factors in colorectal cancer
- Gastrointestinal Tumor Research and Treatment
Which keywords describe Waki Hosoda's research?
The keywords of their largest research topics: Chemotherapy, Immunotherapy, Pancreatic Cancer, Surgical Complications, Prognostic Factors, Targeted Therapy, Neuroendocrine Tumors and Pancreatic Neuroendocrine Tumors.
- Sunitinib
- Molecular Characterization
- Cholangiocarcinoma
- Mutational Signatures
- Chronic Pancreatitis
- Small-Cell Lung Cancer
- Surgical Management
- Pancreatic Neuroendocrine Tumors
- Targeted Therapy
- Surgical Complications
- Immunotherapy
- Chemotherapy
- Pancreatic Cancer
- Prognostic Factors
- Neuroendocrine Tumors
- Epidemiology
- Genomic Profiles
- Acute Pancreatitis
- Cancer Genomics
- Biliary Tract Cancer
- Microsatellite Instability
- Imatinib Mesylate
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Chemotherapy702 topics
- Immunotherapy702 topics
- Pancreatic Cancer481 topic
- Surgical Complications481 topic
- Prognostic Factors453 topics
- Targeted Therapy372 topics
- Neuroendocrine Tumors321 topic
- Pancreatic Neuroendocrine Tumors321 topic
- Epidemiology302 topics
- Surgical Management232 topics
- Genomic Profiles221 topic
- Small-Cell Lung Cancer221 topic
- Acute Pancreatitis171 topic
- Chronic Pancreatitis171 topic
- Cancer Genomics151 topic
- Mutational Signatures151 topic
- Biliary Tract Cancer131 topic
- Cholangiocarcinoma131 topic
- Microsatellite Instability111 topic
- Molecular Characterization111 topic
- Imatinib Mesylate101 topic
- Sunitinib101 topic
Where does Waki Hosoda work?
Waki Hosoda's main affiliation in the publication record is Aichi Cancer Center, Japan.
How many publications and citations does Waki Hosoda have?
OpenAlex counts 168 works and 3,658 citations for Waki Hosoda, an h-index of 33, ranking #679,315 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Waki Hosoda. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.